[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356783-105":59,"doc-detail-356783-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","prospective-evaluation-of-genomics-guided-off-label-treatment","Prospective evaluation of genomics-guided off-label treatment","","Prospective evaluation of genomics-guided off-label treatment in the DRUP trial enrolled inpatients in the Netherlands with advanced solid tumours lacking standard options and carrying actionable genomic alterations. Results cover 1,610 patients starting 37 different off-label drugs; 1,363 were response-evaluable, including 533 rare-cancer cases. The clinical benefit rate was 34.9% and objective response rate 15.7%, with median progression-free survival 3.4 months and overall survival 8.2 months. Grade 3+ treatment-related adverse events occurred in 28.4%, with molecular subgroups and exceptional responders showing meaningful benefit. Evidence informed reimbursement decisions, supporting frameworks for systematic efficacy and toxicity assessment, biomarker refinement and regulatory-aligned endpoints.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prospective-evaluation-of-genomics-guided-off-label-treatment/356783/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prospective-evaluation-of-genomics-guided-off-label-treatment/356783.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the DRUP trial evaluate in off-label cancer treatment?","Question",{"text":113,"@type":114},"It prospectively evaluates genomics-guided off-label use in inpatients with advanced solid tumours who lack standard treatment options and have actionable genomic alterations.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients and drugs were included in the reported results?",{"text":118,"@type":114},"The results include 1,610 patients who started 37 different off-label drugs between July 2016 and May 2024.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main efficacy and safety outcomes?",{"text":122,"@type":114},"Clinical benefit rate was 34.9% and objective response rate was 15.7%. Grade 3 or higher treatment-related adverse events occurred in 28.4% of patients.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356783,1790211933,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Prospective evaluation of genomics-guided off-label treatment  \n\n| [https://doi.org/10.1038/s41586-026-10405-x](https://doi.org/10.1038/s41586-026-10405-x)\u003Cbr>Received: 2 September 2025 Accepted: 11 March 2026 Published online: 15 April 2026 Open access\u003Cbr> Check for updates | K. Verkerk1,2, A. C. Spiekman3,41, S. F. Haj Mohammad1,4,41, F. A. J. Verbeek1,2,41, H. Timmer1,4,41, M. A. van Maren3,41, L. J. Zeverijn1,2, B. S. Geurts1,2, V. van der Noort5, P. Roepman6,\u003Cbr>A. M. L. Jansen7, W. W. J. de Leng7, H. Gelderblom4, H. M. W. Verheul3, E. E. Voest1,2 ✉ & The DRUP Trial Investigators*\u003Cbr>Anticancer drugs are frequently used off-label for tumours that are genetically similar to the approved indication. However, outcomes are rarely captured systematically, limiting evidence-based decision-making and risking repeated futile treatment. The Drug Rediscovery Protocol (DRUP; ClinicalTrials.gov ID: NCT02925234) prospectively evaluates such off-label use inpatients in the Netherlands with advanced solid tumours who lack standard treatment options and harbour actionable genomic alterations1. Here we present results of 1,610 patients who began treatment with 37 different off-label drugs between July 2016 and May 2024 intheDRUP trial. Of these patients, 1,363 were response-evaluable, including 533 (39.1%) with rare cancers. The clinical benefit rate (confirmed response or stable disease for at least 16 weeks) was 34.9%(95% confidence interval, 32.2–37.6) and the objective response rate was 15.7%(95% confidence interval, 13.7–17.9). Median progression-free and overall survival were 3.4 months (95% confidence interval, 2.8–3.5) and 8.2 months (95% confidence interval, 7.6–8.8), respectively. Grade 3 or higher treatment-related adverse events occurred in 28.4% of patients. Notably, evidence generated inDRUP was used for reimbursement decisions by the regulatory bodies in the Netherlands2. Although activity across all tumour–drug combinations was modest, defined molecular subgroupsand exceptional responders (7.0%) achieved meaningful benefit. To maximize patient benefit, we recommend that off-label precision medicines should be used only within frameworks that systematically evaluate efficacy and toxicity, support biomarker refinement and enable stepwise assessment toward potential future label expansion. These frameworks should prioritize high-confidence targets, early intervention, regulatory-aligned end-points and international collaboration. |  |\n| --- | --- | --- |\n| Patients with advanced or metastatic cancer who have exhausted all |  | their established safety profiles and dosing over experimental phase |\n| approved treatments often seek additional therapeutic options. The |  | I agents6. Consequently, off-label use, defined as prescribing drugs |\n| rise of social media, patient advocacy groups and other information |  | beyond their US Food and Drug Administration or European Medicines |\n| sources have made patients and physicians increasingly well-informed |  | Agency approval, is widespread: a recent analysis of 165,912 US patients |\n| and proactive3, including regarding preliminary studies and case |  | with 14 common cancer types found that 18.6% received at least one |\n| reports suggesting that drugs approved for one cancer type maybe |  | off-label therapy7. |\n| effective against another. This is especially relevant for patients with |  | Given that the development of successful anticancer drugs is an |\n| rare cancers, who face limited treatment options and poorer outcomes |  | expensive and lengthy process, with estimated attrition rates exceeding |\n| owing to reduced trial opportunities and commercial incentive for |  | 95%(ref.8), repurposing approved therapies beyond their original indi- |\n| drug development in small populations4. The expanding role of tar- |  | cations offers a pragmatic strategy to accelerate access to treatments |\n| geted therapies in oncology further reinforces this trend, as many |  | and improve the o","cbCaiar1DiaKWn1y","https://ap.wps.com/l/cbCaiar1DiaKWn1y","pdf",4871912,21,"English","# Overview\n## Study design and eligibility\n## Patient outcomes and efficacy\n## Safety and key findings\n# Clinical implications","[{\"question\":\"What does the DRUP trial evaluate in off-label cancer treatment?\",\"answer\":\"It prospectively evaluates genomics-guided off-label use in inpatients with advanced solid tumours who lack standard treatment options and have actionable genomic alterations.\"},{\"question\":\"How many patients and drugs were included in the reported results?\",\"answer\":\"The results include 1,610 patients who started 37 different off-label drugs between July 2016 and May 2024.\"},{\"question\":\"What were the main efficacy and safety outcomes?\",\"answer\":\"Clinical benefit rate was 34.9% and objective response rate was 15.7%. Grade 3 or higher treatment-related adverse events occurred in 28.4% of patients.\"}]","Prospective evaluation of genomics-guided off-label treatment | PDF",1790127280,53,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/985951c46296ec917cc377af6959bde1.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c4ca5e82f61702c598b2a17b9f9e100.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddc9bb0fd69443bde808535e64524967.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c101e6942891febd8bb8de0017bc6c9.webp",980,1301]